TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease

TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease: "TorreyPines Therapeutics, Inc. today announced completion of its second Phase I study with NGX267 in clinical development for the treatment of Alzheimer's disease. This study evaluated the safety of NGX267 in healthy elderly volunteers. In a previous Phase I study, NGX267, administered as single doses, was shown to be well-tolerated in healthy, younger adult males. NGX267, a selective cholinergic muscarinic, or M1, receptor agonist, has demonstrated potential in providing both symptomatic improvement and disease modification in animal models of Alzheimer's disease."